BioSpace News Archive

Amwell ® , (NYSE: AMWL) (the “Company”) a national telehealth leader, today announced that it will report third quarter ended September 30, 2020 operating results on Thursday, November 12, 2020 . Following distribution of the earnings release via wire services, the Amwell management team will host a live conference call and webcast

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced that it has been issued U.S. patent number 10815271 (application number 16/311,593) from the United States Patent and Trademark Office (USPTO) covering the composition of matter for SLS-007,

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer announced today that the U.S. Food and Drug Administration (“FDA”) has cleared the Company’s Investigational New Drug (“IND”) application for 177 Lu-omburtamab-DTPA for the treatment of B7-H3 positive Central Nerv

SeaStar Medical, a medical technology company delivering novel therapeutic immunomodulating solutions to improve organ function, today announced the results from the first every application of the Selective Cytopheretic Device (SCD) in pediatric patients with acute kidney injury (AKI) requiring continuous renal replacement therapy (CRRT).

Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration (“U.S. FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19.

Zomedica Corp. (NYSE American: ZOM) announced today that the following letter from Robert Cohen, Interim Chief Executive Officer, has been made available to shareholders. Dear Shareholders: I am writing to you today with a single, straightforward message -- please vote for the domestication proposal described in our proxy materials for our virtual Special Meeting to be held on December 15, 2020. Approval of the domestication proposal wi

NICCI is Getinge’s latest innovation in Advanced Hemodynamic Monitoring, providing continuous and noninvasive hemodynamic insights to reduce the risk of severe complications for patients with low blood pressure

Echosens , a high-technology company offering the FibroScan family of products, urges increased awareness of the rise of liver cancer rates, which have more than tripled since 1980, while death rates have more than doubled during this time. About 21,000 Americans are diagnosed with primary liver cancer each year—twice as common in men than in women. Risk factors include other liver diseases, including cirrhosis, chro

Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received U.S. Food and Drug Administration (FDA) approval for the Abre™ venous self-expanding stent system. This device is

Today, Ginkgo Bioworks announced it has secured access to the SD Biosensor rapid antigen test with a goal of acquiring and distributing up to 50 million tests. Concentric by Ginkgo , the company’s CO